Back to Search Start Over

Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid®Treatment on Cognition and 18F-FDG PET Scans

Authors :
Manzano Palomo, Maria Sagrario
Anaya Caravaca, Belen
Balsa Bretón, Maria Angeles
Castrillo, Sergio Muñiz
Vicente, Asuncion de la Morena
Castro Arce, Eduardo
Alves Prez, María Teresa
Source :
Journal of Alzheimer's Disease Reports; November 2019, Vol. 3 Issue: 1 p95-102, 8p
Publication Year :
2019

Abstract

Background: Previous studies have shown that Souvenaid (medical food) can have benefits on memory, cognition, and function in early Alzheimer’s disease (AD) and mild cognitive impairment (MCI).Objective: Demonstrate that Souvenaid could improve or maintain cognition and has an effect on neurodegeneration biomarkers.Methods: This cohort study was carried out from June 2015 through December 2016 in the Neurology Department, Infanta Cristina Hospital, Madrid, Spain. MCI-HR-AD were recruited using Petersen criteria, neuropsychology (NPS), and 18F-FDG PET scans to confirm the high risk of progression to dementia with one year of follow-up. Age, sex, vascular risk factors (VRF), and NPS values (Barcelona brief version) were analyzed. 18F-FDG PET scans were analyzed as a visual procedure. The study was approved by the Research Committee of ICH. Statistical analysis was made with SPSS 22.0 version.Results: Subjects included 43 MCI patients (58.5% women; mean age 69.78±7.89): 17 receiving Souvenaid®treatment (ST), 24 receiving no treatment (WT) and 2 who withdrew. No differences were seen in VRF, only hypercholesterolemia, and were less prevalent in the ST group (p?=?0.002). The rate of progression to dementia was 48.8% (no differences between groups, p?=?0.654). A second round of 18F-FDG PET scans showed a significance worsening of glucose metabolism in WT (p?=?0.001) versus ST, in which it was low (p?=?0.050). For NPS testing, there was a significant worsening in memory performance in the WT group (p?=?0.011) and a stabilization in ST (p?=?0.083), as well as in executive functions and attention (worsening in WT, p?=?0.014). For the Subjective Changing Scale (SCS), caregivers indicated a stabilization/improvement in ST (p?=?0.017).Conclusion: Souvenaid had a significant effect on several cognitive domains, and on SCS in patients with MCI-HR-AD. Its intervention had an impact on preservation on 18F-FDG PET scans.

Details

Language :
English
ISSN :
25424823 and 25424823
Volume :
3
Issue :
1
Database :
Supplemental Index
Journal :
Journal of Alzheimer's Disease Reports
Publication Type :
Periodical
Accession number :
ejs67499734
Full Text :
https://doi.org/10.3233/ADR-190109